PTC Therapeutics, Inc. (NASDAQ:PTCT)’s share price reached a new 52-week high on Tuesday . The company traded as high as $31.83 and last traded at $31.77, with a volume of 470733 shares traded. The stock had previously closed at $30.12.
A number of equities analysts have weighed in on the stock. Zacks Investment Research raised shares of PTC Therapeutics from a “hold” rating to a “buy” rating and set a $31.00 price target on the stock in a research note on Saturday, March 10th. Barclays reaffirmed an “equal weight” rating and set a $24.00 price target (up previously from $18.00) on shares of PTC Therapeutics in a research note on Wednesday, March 7th. William Blair reaffirmed a “hold” rating on shares of PTC Therapeutics in a research note on Wednesday, March 7th. Citigroup increased their price target on shares of PTC Therapeutics from $24.00 to $35.00 and gave the stock a “buy” rating in a research note on Wednesday, February 21st. Finally, Credit Suisse Group reaffirmed a “buy” rating and set a $28.00 price target on shares of PTC Therapeutics in a research note on Tuesday, January 30th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and three have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $23.57.
The firm has a market cap of $1,252.98, a PE ratio of -15.21 and a beta of 1.71. The company has a quick ratio of 2.90, a current ratio of 3.04 and a debt-to-equity ratio of 0.93.
PTC Therapeutics (NASDAQ:PTCT) last released its quarterly earnings data on Tuesday, March 6th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.17. PTC Therapeutics had a negative net margin of 40.64% and a negative return on equity of 50.75%. The company had revenue of $78.00 million during the quarter, compared to analyst estimates of $78.59 million. During the same quarter in the prior year, the business earned ($0.78) earnings per share. The business’s quarterly revenue was up 209.5% compared to the same quarter last year. equities analysts predict that PTC Therapeutics, Inc. will post -1.4 EPS for the current year.
In other news, CEO Stuart Walter Peltz sold 2,230 shares of the stock in a transaction on Friday, January 5th. The shares were sold at an average price of $18.03, for a total value of $40,206.90. Following the completion of the sale, the chief executive officer now owns 26,646 shares of the company’s stock, valued at $480,427.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 2,719 shares of company stock valued at $48,848 in the last three months. Company insiders own 8.10% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the company. Macquarie Group Ltd. acquired a new stake in shares of PTC Therapeutics in the third quarter worth $102,000. Quantbot Technologies LP acquired a new stake in shares of PTC Therapeutics in the third quarter worth $150,000. MANA Advisors LLC acquired a new stake in shares of PTC Therapeutics in the fourth quarter worth $221,000. Teacher Retirement System of Texas acquired a new stake in shares of PTC Therapeutics in the fourth quarter worth $228,000. Finally, Los Angeles Capital Management & Equity Research Inc. acquired a new stake in shares of PTC Therapeutics in the third quarter worth $229,000. 91.77% of the stock is owned by institutional investors.
PTC Therapeutics Company Profile
PTC Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation.
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.